Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 31 to 40 of 295

TitleType
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550Technology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]Technology appraisal guidance
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years TSID 12054Technology appraisal guidance
BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis TS ID 10334Technology appraisal guidance
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592Technology appraisal guidance
Botulinum toxin type A for preventing episodic migraine ID 6450Technology appraisal guidance
Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over ID 6448Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All